Delivery of antisense oligonucleotides for splice‐correction of androgen receptor pre‐mRNA in castration‐resistant prostate cancer models using cell‐penetrating peptides

Protein Expression Correlates Linearly with mRNA Dose over Up to Five Orders of Magnitude In Vitro and In Vivo

(2021) Alexander H. van Asbeck et al.   Biomedicines

Suppression of prostate tumor cell survival by antisense oligonucleotide-mediated inhibition of AR-V7 mRNA synthesis

(2019) Maria V. Luna Velez et al.   ONCOGENE

Peptide-mediated delivery of therapeutic mRNA in ovarian cancer

(2019) Dirk van den Brand et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

The potential of AR-V7 as a therapeutic target

(2018) Takuma Uo et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Cell-penetrating peptides for siRNA delivery to glioblastomas

(2018) Artita Srimanee et al.   PEPTIDES

Assisted delivery of antisense therapeutics in animal models of heritable neurodegenerative and neuromuscular disorders: a systematic review and meta-analysis

(2018) M. Leontien van der Bent et al.   Scientific Reports

Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy

(2017) Matthias Eiber et al.   JOURNAL OF NUCLEAR MEDICINE

Effective in vivo gene delivery with reduced toxicity, achieved by charge and fatty acid -modified cell penetrating peptide

(2017) Kaido Kurrikoff et al.   Scientific Reports

Delivery of therapeutic oligonucleotides with cell penetrating peptides

(2015) Prisca Boisguérin et al.   ADVANCED DRUG DELIVERY REVIEWS

PEG shielded MMP sensitive CPPs for efficient and tumor specific gene delivery in vivo

(2015) Kadi-Liis Veiman et al.   JOURNAL OF CONTROLLED RELEASE

Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy

(2015) B. Meller et al.   EJNMMI Research

AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

(2014) Emmanuel S. Antonarakis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Stereoselective Uptake of Cell-Penetrating Peptides is Conserved in Antisense Oligonucleotide Polyplexes

(2014) Marco Emanuele Favretto et al.   Small

Molecular Parameters of siRNA–Cell Penetrating Peptide Nanocomplexes for Efficient Cellular Delivery

(2013) Alexander H. van Asbeck et al.   ACS Nano

Androgen Receptor Splice Variants Mediate Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cell Lines

(2012) Y. Li et al.   CANCER RESEARCH

Preferential Uptake of L- versus D-Amino Acid Cell-Penetrating Peptides in a Cell Type-Dependent Manner

(2011) Wouter P.R. Verdurmen et al.   CHEMISTRY & BIOLOGY

PepFect 14, a novel cell-penetrating peptide for oligonucleotide delivery in solution and as solid formulation

(2011) Kariem Ezzat et al.   NUCLEIC ACIDS RESEARCH

A Cell-penetrating Peptide Derived from Human Lactoferrin with Conformation-dependent Uptake Efficiency

(2009) Falk Duchardt et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents

(2009) C. A. Stein et al.   NUCLEIC ACIDS RESEARCH

Heterogeneity of Prostate-Specific Membrane Antigen (PSMA) Expression in Prostate Carcinoma with Distant Metastasis

(2009) Sebastian Mannweiler et al.   PATHOLOGY & ONCOLOGY RESEARCH

Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer

(2008) R. Hu et al.   CANCER RESEARCH